The Shentel Cares Team is donating time and a check to the Virginia Peninsula Foodbank in May.
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell ...
Kinertic provides commodity producers, traders and buyers with a carbon intelligence platform integrated into their existing systems, connected with trade capture systems to map flows, aggregate ...
Hong Kong, Aug. 12, 2026 (GLOBE NEWSWIRE)-- Ming Shing Group Holdings Limited (the "Company” or "Ming Shing”) (NASDAQ: PMA), a Hong Kong-based company mainly engaged in wet trades works, today ...
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant ...
Residential solar demand and consolidated revenue declined year over year following the loss of the 25D federal residential tax credits resulting from the One Big Beautiful Bill Act, effective January ...
Achieved alignment with the U.S. Food and Drug Administration (FDA) on a proposed imdusiran Phase 2b clinical trial design WARMINSTER, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE)-- Arbutus Biopharma ...
GAITHERSBURG, Md., Aug. 12, 2026 (GLOBE NEWSWIRE)-- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ...
New Paybis research finds users prefer exact fee amounts, itemized cost breakdowns, and visibility into what actually lands in their wallet before confirming a transaction. Paybis, a global crypto and ...
- Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study - ...
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant ...
On Track to Complete Enrollment of the Phase 3 ELAINE-3 clinical trial in 4Q 2026 with Topline Data Expected in 2H 2027 BOTHELL, Wash., Aug. 12, 2026 (GLOBE NEWSWIRE)-- LeonaBio, Inc. (NASDAQ: LONA), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results